Markets

Boston Scientific Captivator EMR to Treat Esophageal Cancer

An image of a globe with financial data surrounding it
Credit: Shutterstock photo

Boston Scientific CorporationBSX recently unveiled its Captivator Endoscopic Mucosal Resection (EMR) Device that has been specifically designed to detect and remove precancerous tissue and early esophageal cancer from a patient's upper gastrointestinal (GI) tract. Currently, this system is available in the U.S., Europe, Singapore, Australia and Puerto Rico.

The launch reflects the company's attempts to bolster its footprint in the global multi-billion dollar endoscopic devices market, wherein the company already holds a prominent position in the GI endoscopic section.

Notably, the Captivator EMR device facilitates a minimally invasive alternative to an esophagectomy - a more invasive and costly surgical procedure - usually adopted to remove some or most of the esophagus in patients diagnosed with cancer in their upper GI tracts.

Currently, esophageal cancer accounts for about 1% of all cancer cases diagnosed in the U.S. However, it is known to be more common in other parts of the world, such as Iran, northern China, India, and southern Africa. People having Barrett's esophagus - a complication of acid reflux disease that causes abnormal change in esophagus tissues - are at the highest risk of contracting esophageal cancer.

It is estimated that out of a population of 1 million to 2 million having Barrett's esophagus, annually, 10,000 to 15,000 people in the U.S. are affected by esophageal cancer. Endoscopic resection of abnormal esophageal tissue growth (called early neoplasia) is a less invasive alternative to treat this condition compared to the more invasive and risky esophagectomy surgical procedure.

We believe the Captivator EMR launch will allow Boston Scientific to capture a larger share in this high-potential EMR space.

For increased adoption of its Captivator EMR device, Boston Scientific recently initiated a multi-center, post-market registry which will enroll up to 300 patients. The primary aim of this study is to evaluate the performance of the Captivator EMR Device in performing early neoplasia, specifically in Barrett's Esophagus patients.

We believe, once the company releases the results of this study post its completion in 2016, demand for Boston Scientific's Captivator EMR device will rise.

With the global market for endoscopy devices expected to reach $36.9 billion in 2019 at a CAGR of 6.8% (from 2013 to 2019), we expect Boston Scientific to enjoy higher profits from its endoscopy business on the back of the aforementioned launch, in particular, going forward.

Currently, Boston Scientific has a Zacks Rank #2 (Buy). Some other top-ranked medical product stocks are Enzymotec Ltd. ENZY , ICU Medical, Inc. ICUI and OraSure Technologies, Inc. OSUR . All the three stocks sport a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

BOSTON SCIENTIF (BSX): Free Stock Analysis Report

ORASURE TECH (OSUR): Free Stock Analysis Report

ICU MEDICAL INC (ICUI): Free Stock Analysis Report

ENZYMOTEC LTD (ENZY): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ICUI BSX OSUR

Other Topics

Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More